Ketamine therapy represents a shift in how medical professionals approach treatment-resistant depression and certain other mental health conditions. Unlike many psychiatric medications that work through conventional pathways in the brain, ketamine operates through a different mechanism that researchers have been studying intensively over the past two decades.
Learn About Paying Your FGUA Bill Online →
Ketamine itself is not new. It was first synthesized in 1962 and received FDA approval as an anesthetic in 1970. For decades, it remained primarily used in surgical settings and emergency medicine. However, beginning in the early 2000s, researchers noticed something unexpected: patients receiving ketamine for anesthesia sometimes reported rapid improvements in depressive symptoms. This observation launched a new area of psychiatric research that has now produced hundreds of peer-reviewed studies.
The current clinical landscape for ketamine therapy includes several forms of administration. Intravenous (IV) ketamine infusions are the most researched format and typically occur in medical clinics over several weeks. Intramuscular injections represent another option. A nasal spray form called esketamine (a specific version of ketamine) received FDA approval in 2019 specifically for treatment-resistant depression. Oral ketamine exists but has less clinical research supporting its use. Each delivery method produces different concentrations in the bloodstream and different timing for effects.
What distinguishes ketamine therapy from standard antidepressants is the speed of response. Traditional SSRIs (selective serotonin reuptake inhibitors) like sertraline or paroxetine typically require 4 to 8 weeks to produce noticeable effects, with full benefits sometimes taking 12 weeks or longer. Ketamine therapy can produce measurable changes in depressive symptoms within hours or days. For individuals experiencing severe depression, this rapid response has meaningful implications.
The conditions being studied for ketamine therapy extend beyond depression. Research is ongoing for treatment-resistant bipolar depression, anxiety disorders, post-traumatic stress disorder (PTSD), and suicidal ideation. However, the strongest evidence currently exists for treatment-resistant major depression—specifically, depression that has not responded adequately to at least two different antidepressant medications taken at therapeutic doses for sufficient periods.
Practical takeaway: Ketamine therapy differs fundamentally from conventional psychiatric medications in mechanism, speed of action, and administration method. Understanding this basic distinction helps frame the actual clinical purpose of the treatment.
The conventional understanding of depression centered on the "monoamine hypothesis"—the idea that depression results from low levels of serotonin, norepinephrine, or dopamine in the brain. This model led to the development of SSRIs and other antidepressants that increase these neurotransmitters. However, this explanation has always been incomplete. Not everyone responds to these medications, and they don't work as quickly as their mechanism would suggest.
Free Guide to Pay by Plate Illinois Billing →
Ketamine therapy operates through a different neurochemical pathway. Ketamine primarily blocks NMDA receptors—a type of glutamate receptor in the brain. Glutamate is the brain's primary excitatory neurotransmitter, and NMDA receptors are crucial for neural communication. By blocking these receptors, ketamine alters how neurons communicate in specific brain regions, particularly in the prefrontal cortex and limbic system areas involved in mood regulation and emotional processing.
What happens after the initial NMDA blockade is where the therapeutic mechanism becomes interesting. This blockade triggers a cascade of events: increased glutamate release in certain areas, activation of AMPA receptors, and ultimately increased production of brain-derived neurotrophic factor (BDNF). BDNF functions as a growth factor that supports neuronal survival and promotes growth of new neurons and synapses. Think of it as fertilizer for neural connections. This neuroplasticity—the brain's ability to form new connections and reorganize itself—appears central to ketamine's antidepressant effects.
Research using brain imaging shows that ketamine produces measurable changes in connectivity between brain regions involved in mood and emotional regulation. Studies using functional MRI (fMRI) demonstrate that individuals with depression show abnormal connectivity patterns in networks like the default mode network. After ketamine administration, these connectivity patterns shift toward patterns more typical of individuals without depression. These changes can occur within hours, which aligns with the rapid symptom improvement observed clinically.
Another emerging area of research involves ketamine's effects on the stress response system. The hypothalamic-pituitary-adrenal (HPA) axis regulates cortisol and other stress hormones. In depression, this system often becomes dysregulated, with abnormal cortisol patterns contributing to mood symptoms. Ketamine appears to help normalize HPA axis function, potentially reducing the physiological stress response that perpetuates depressive states.
Importantly, the neuroscience of ketamine therapy remains an active research frontier. Scientists continue to refine understanding of which specific mechanisms drive the therapeutic effects and why some individuals respond while others don't. The complexity of the brain means that the full picture likely involves multiple overlapping mechanisms rather than a single explanation.
Practical takeaway: Ketamine works through glutamate pathways and neuroplasticity mechanisms fundamentally different from conventional antidepressants. This different mechanism explains both why it may work for treatment-resistant cases and why its effects can appear more rapidly.
The practical experience of ketamine therapy differs substantially depending on which form a patient receives. Understanding the specifics matters because administration method affects everything from frequency of appointments to intensity of monitoring to potential side effects.
Free Guide to Mold Removal Methods for Walls →
Intravenous ketamine infusion remains the most commonly studied and clinically utilized form. A typical protocol involves patients attending a clinic or medical facility for infusions usually lasting 40 to 45 minutes. Initial treatment protocols frequently consist of six infusions over two weeks—for example, three infusions in week one and three in week two. Dosing typically ranges from 0.5 to 2.0 mg per kilogram of body weight, adjusted based on individual response and tolerance. A patient weighing 70 kilograms might receive approximately 35 to 140 mg per infusion depending on the specific protocol and clinical judgment.
During an IV infusion, patients are seated in a comfortable chair or reclined in a medical setting. A qualified healthcare provider places an IV line, and ketamine is delivered directly into the bloodstream. Vital signs including blood pressure, heart rate, and oxygen saturation are continuously monitored. The experience during the infusion can vary considerably between individuals. Some report a dissociative feeling—a sense of detachment from their body or surroundings. Others describe visual or perceptual changes. These dissociative effects typically resolve within minutes to an hour after the infusion ends. Some individuals experience nausea during or after the infusion, though this can often be managed with anti-nausea medications given before treatment.
Esketamine nasal spray (marketed as Spravato) represents a different delivery method. Esketamine is specifically the S-enantiomer of ketamine—essentially a particular molecular configuration with potentially stronger effects. The nasal spray formulation delivers ketamine through the nasal mucosa directly into the bloodstream. Treatment typically involves clinic visits twice per week initially, with patients self-administering the nasal spray under direct medical supervision. Patients remain at the clinic for observation typically for about two hours after each dose. This format allows for treatment at home, which some find preferable to repeated clinic visits.
Intramuscular ketamine injections offer another option, sometimes used when IV access is difficult or when patients prefer not to spend extended time in a clinic setting. Injections deliver ketamine into muscle tissue, where it's absorbed into the bloodstream more slowly than IV administration but more rapidly than oral forms. An intramuscular injection for ketamine therapy might deliver 75 to 100 mg, with effects typically noticeable within 15 to 20 minutes.
Following the initial intensive treatment phase, maintenance protocols vary. Some individuals may return for infusions monthly or every few months. Others may transition to oral ketamine, though research on oral forms remains more limited than for IV or intranasal administration. The decision about maintenance treatment depends on individual response, symptom relapse, and ongoing clinical assessment.
Throughout ketamine therapy, medical professionals assess changes in depressive symptoms, suicidal thinking, and overall functioning using standardized rating scales. The Montgomery-Åsberg Depression Rating Scale (MADRS
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.